---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Integrated externally controlled survival analysis"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Integrated externally controlled survival analysis. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 56 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/integrated-externally-controlled-survival-analysis"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Integrated externally controlled survival analysis

<a id="heading-3.1.1"></a>

## 3.1.1 Integrated Externally Controlled Survival Analysis

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Objective of the FDA integrated survival analysis

> “To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-3.1.1.1-2"></a>

#### Objectives of the company-presented survival analysis with broader external controls

> “The primary objective was to compare OS (baseline to death or last known alive) in patients with early and late I-NPC treated with adrabetadex vs external controls receiving usual care”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “Compare survival among individuals with infantile-onset NPC treated with adrabetadex to matched external controls”
> “Evaluate long-term disease progression in adrabetadex-treated individuals”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

<a id="topic-3.1.1.1-3"></a>

#### Objective of the target trial emulation framework

> “To apply a target trial emulation framework to identify and address potential sources of bias in an externally controlled survival analysis of adrabetadex in I-NPC.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.1-4"></a>

#### Objectives proposed in the 2021 data request for external controls

> “To determine 1) if early onset patients with NPC treated with adrabetadex show improved survival and delay in loss of ambulation relative to matched untreated patients and 2) if patient cohorts treated long-term with adrabetadex progress more slowly than natural history controls.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.1-5"></a>

#### Objective of the NIH natural history study used as the external control

> “The purpose of this protocol is to obtain both baseline and rate of progression data on clinical and biochemical markers that may later be used as an outcome measure in a clinical trial.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### NIH natural history study site

> “Participants undergo the following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="topic-3.1.1.2-2"></a>

#### Data cutoff of the company-presented survival analysis, January 2025

> “OS analysis cutoff was January 10, 2025”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.2-3"></a>

#### International registry and French cohort contributing external controls

> “NPC Registry (AC-056C501) is an international, multi-center, prospective, observational, long-term project for patients diagnosed with NP-C”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.2-4"></a>

#### Database lock of the prior sponsor's studies, December 2021

> “The Mallinckrodt databases were locked in December 2021 but other data sources are not yet available.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.2-5"></a>

#### Data cutoff of the company-presented survival analysis, September 2025, superseded in February 2026

> “Miglustat use was permitted; other recently approved therapies were not prohibited in the EAP, but exposure was minimal before the overall survival analysis cutoff (June 24, 2024).”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Integrated survival analysis as the basis of effectiveness in the label

> “The effectiveness of LEMBAZ to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with NPC with neurological manifestations onset prior to 6 years of age was established based on an integrated survival analysis of data from Trials 1, 2, 3, an expanded access program, and Study 1.”
> “Study 1 is an observational, prospective, natural history study of patients with NPC regardless of age or age of neurological manifestation onset.”
> “Matching was based on disease subtype (early vs. late infantile-onset), age of neurological symptom onset (±3 months), and baseline miglustat use (yes vs. no) using a many-to-one matching algorithm.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.3-2"></a>

#### FDA determination that the externally controlled comparison was the adequate and well-controlled study

> “The efficacy of LEMBAZ was based on an overall survival analysis in people with I-NPC treated with LEMBAZ across three clinical studies and an Expanded Access Program, compared with matched external controls.”
> “The FDA determined that this comparison served as the adequate and well-controlled study supporting approval.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-3.1.1.3-3"></a>

#### Externally controlled analysis submitted as a single adequate and well-controlled study

> “The NDA for adrabetadex is supported by data demonstrating a clinically meaningful survival benefit in infantile-onset patients.”
> “This evidence is from an externally controlled analysis intended to serve as a single adequate and well-controlled study.”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

<a id="topic-3.1.1.3-4"></a>

#### Design rationale stated in the 2021 data request

> “In NPC, placebo/sham-controlled trials are highly challenging due to variability of the disease (1,13), slow progression over years, and limited numbers of patients.”
> “The phase 2b/3 trial of adrabetadex in NPC was subject to all these issues and the control group failed to progress at a rate that would allow a definitive determination of drug effect for adrabetadex (7).”
> “Each patient with disease onset under age 5 years who has been treated with adrabetadex will be matched to as many historical controls as possible from this database and other sources, based on developmental milestones and clinical features and will be compared with respect to age of loss of ambulation and death, as well as other secondary outcomes to be determined based on data available.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.3-5"></a>

#### Company-presented survival analysis with broader external controls: data sources

> “Participants were pooled from the phase 2b/3 trial with open-label extension (VTS301: Parts A/B [NCT02534844] and Part C [NCT04958642, which included participants from Parts A/B and the phase 1/2a study, NCT01747135]) and from Expanded Access Program (EAPs; RUSH IND 119856, VTS-270-001, and Canadian Special Access Program)”
> “This study was sponsored by Mandos, a subsidiary of Beren Therapeutics P.B.C.”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “OS was compared with matched external controls from 4 major disease databases or publications.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “The survival analysis compared adrabetadex-treated individuals (n=72) with infantile neurological onset NPC who participated in a Phase 2b/3 trial and open-label extension period and/or in an Expanded Access Program (EAP) to 119 matched external controls from the NIH Natural History study and three other major disease databases or publications.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.3-6"></a>

#### Company-presented survival analysis with broader external controls: target trial emulation

> “Evaluation of therapeutic efficacy in rare diseases may require external controls when data from randomized controlled trials are not available.”
> “Analysis included matched adrabetadex-treated participants from an expanded access program, Phase 1/2a, and Phase 2b/3 studies (n=72) and unique external control participants from prospectively and retrospectively collected natural history cohorts (n=119).”
> “Matching factors included disease subtype, age at neurological onset, age at index, and miglustat use at index.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Company-presented disease progression analysis in treated participants

> “Matching Algorithm Addresses the Most Important Prognostic Factors”
> “Disease progression was assessed in 79 infantile-onset individuals from clinical trials and EAP”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

> “The annual rate of clinical disease progression assessed by R4DNPCCSS during adrabetadex treatment was compared with pre-treatment periods.”
> “A longitudinal mixed effects model estimated mean annual rates of change pre- and post-adrabetadex treatment, with R4DNPCCSS scores imputed as 0 at birth to anchor trajectories”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.3-8"></a>

#### Company-presented survival analysis matching, September 2025, superseded in February 2026

> “External controls were matched to adrabetadex-treated participants using a many-to-one algorithm based on baseline age, age at neurological symptom onset, and miglustat use, with weighting to allow reuse of controls.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Neurological onset before 6 years of age in the label analysis

> “The integrated survival analysis using these data sources included only patients with neurological manifestations onset prior to 6 years old”
> “The matching also required the matched untreated patient from Study 1 to be alive at the age that the treated patient started LEMBAZ treatment (referred to as the index age for a matched stratum).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “All patients had neurological manifestations of NPC that occurred prior to age 6.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-3.1.1.4-2"></a>

#### NIH natural history study enrollment

> “Patients of any age with NPC may be eligible for this study.”
> “All patients with a diagnosis of NPC, based on clinical presentation, biochemical, or molecular.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="topic-3.1.1.4-3"></a>

#### Company-presented survival analysis with broader external controls: eligibility for matching

> “Match-eligible adrabetadex-treated participants had early or late infantile-onset NPC and received ≥1 dose of adrabetadex”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “Addressed by setting each control's index age to the matched treated participant's age at adrabetadex initiation, with controls required to be alive and already enrolled in their prospective study at that age”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.4-4"></a>

#### Inclusion and exclusion criteria proposed in the 2021 data request

> “Aim 1 inclusion criteria will be children with NPC treated with adrabetadex prior to age 5 years due to neurological symptom onset under age 5 years and untreated matched controls from all sources.”
> “Patients will be excluded from both Aims if they have medical complications or additional diagnoses that would impact the course of NPC.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Treatment exposure and dosage in the label analysis

> “LEMBAZ-treated patients were exposed to LEMBAZ for a median duration of 3.6 years (range: 1.4 months to 8.7 years).”
> “The median final LEMBAZ dosage among the treated patients was 750 mg (range: 300 to 1,050 mg) (the maximum recommended dosage is 900 mg every two weeks).”
> “All studies allowed the concomitant use of miglustat.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.5-2"></a>

#### Company-presented survival analysis with broader external controls: dosing across source studies

> “Adrabetadex was administered intrathecally via lumbar puncture at doses of 50–1200 mg every 4 weeks (Q4W) in phase 1/2a and 900–1800 mg every 2 weeks (Q2W) in VTS301 Part A; 900 mg Q2W was selected as the recommended regimen for VTS301 Parts B and C.”
> “Dose reduction was allowed to manage tolerability.”
> “In the EAPs, participants started at 200 or 400 mg (depending on age) Q2W with titration up to 1200 mg (initially) or 900 mg (later revision)”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.5-3"></a>

#### Company-presented survival analysis with broader external controls: concomitant NPC therapies

> “Miglustat use was permitted; other recently approved therapies were not prohibited in the EAP, but exposure was minimal before the OS analysis cutoff (January 10, 2025)”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Treatment definition proposed in the 2021 data request

> “For both Aim 1 and Aim 2 the main predictor/independent variable will be treatment with intrathecal adrabetadex continuously for at least one year.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Overall Survival as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Overall survival definition in the label analysis

> “The survival time was calculated as the time between the index age and the age of last follow-up or death.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.6.1-2"></a>

##### Survival as an outcome in very young children with the fastest progression

> “The only way to truly understand the drug effect in this situation is to look at long-term data and compare treated cohorts with available natural history cohorts, look at within patient pre- and post-treatment rates of decline, and use case-control designs to study very young children who were not a part of the phase 2b/3 trial and who have the fastest rate of progression, thus allowing for the shortest treatment time to pass before outcomes like survival can be assessed.”
> “The overall survival OS is defined as the time from the study entry or randomization to death from any cause.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.6.1-3"></a>

##### Age of neurological onset as the predictor of survival

> “NPC is clinically heterogeneous, with age of neurological symptom onset being the most reliable clinical predictor of disease severity and survival.”
> “Earlier onset is associated with more rapid progression and poorer prognosis, with death often occurring by 5 years of age in early infantile-onset and between 7 and 12 years in late infantile onset.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Usual care as the comparator

> “Usual care for NPC has historically involved management of symptoms, with no cure and limited impact on survival.”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Secondary measure in the company-presented analysis: rescored 4-domain NPC Clinical Severity Scale

> “Disease progression can be assessed using a short-form NPC Clinical Severity Scale (Rescored 4-Domain NPC Clinical Severity Scale [R4DNPCCSS]), which evaluates ambulation, speech, fine-motor function, and swallowing”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “Neurological disease progression was assessed pre- and post-adrabetadex-treatment using the 4-Domain Composite NPC Clinical Severity Scale (4DNPCCSS) of ambulation, speech, fine-motor function and swallowing.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Treated and external control participants in the label analysis

> “A total of 44 control patients with NPC whose neurological manifestations started prior to 6 years of age from Study 1 were eligible for matching to LEMBAZ-treated patients in the integrated survival analysis.”
> “Thirty-six (36) LEMBAZ-treated patients with NPC with neurological manifestations that started at less than 6 years of age from Trials 1, 2, 3, and the expanded access program were matched to external control patients with NPC from Study 1.”
> “The analysis included a total of 26 patients in the external control group from Study 1.”
> “The weighted number of control patients was 36.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.7.1-2"></a>

##### Company-presented survival analysis with broader external controls: 72 treated and 119 matched controls

> “Of 80 total participants treated with adrabetadex eligible for matching, 72 (32 early infantile; 40 late infantile) were successfully matched, with a median treatment duration of 3.8 years (range 0.1–11.1 years).”
> “Of the pooled 255 I-NPC external controls eligible for matching, 119 (57 early infantile; 62 late infantile) were successfully matched”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Sample size in the 2021 data request

> “All planned statistical analyses are exploratory.”
> “No sample size will be calculated, and no minimum sample size was determined a priori.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.7.1-4"></a>

##### Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026

> “Of 78 total adrabetadex-treated participants eligible for matching, 66 (32 early; 34 late) were successfully matched, with a median treatment duration of 3.0 years (range 0.2–9.8).”
> “Of the pooled 246 infantile-onset external controls eligible for matching, 110 (53 early; 57 late) were successfully matched.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Index age, weighting, and statistical models in the label analysis

> “The index age was defined as age at initiation of LEMBAZ treatment for a LEMBAZ-treated patient and its matched control patients.”
> “Control patient data were weighted by the inverse of the total number of matched controls of the LEMBAZ-treated patient.”
> “Estimated from weighted Kaplan-Meier method up to the maximum follow-up time (110 months) in the LEMBAZ-treated group.”
> “Hazard ratio (95% CI) was generated from a weighted Cox regression model including treatment (LEMBAZ-treated vs. matched controls) as fixed effect, and baseline miglustat as a covariate.”
> “The number at risk for the external control group from Study 1 is the rounded integer value of the total sum of the weights for patients at risk.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Company-presented survival analysis with broader external controls: statistical models and censoring

> “Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a weight-adjusted Cox regression model including treatment (adrabetadex-treated vs matched controls) as fixed effect, and history of miglustat as a covariate”
> “Log-rank P-values were calculated using a weight-adjusted Kaplan-Meier (KM) analysis. Subgroup OS analyses included baseline miglustat use and participants with early and late I-NPC”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “those lost to follow-up or still alive at the last available follow-up were censored”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Company-presented survival analysis with broader external controls: matching with replacement and robust variance

> “For the primary overall survival analysis, external controls were selected based on fitness-for-purpose evaluation and analysed using variable-ratio many-to-one matching with replacement, robust (sandwich) variance with clustering on unique control identifiers, and a frequency-based weight equal to the inverse of the number of controls matched to each treated participant.”
> “The treatment effect was estimated from a weight-adjusted Cox proportional hazards regression model with fixed effects for treatment and baseline miglustat history.”
> “Prespecified subgroup and sensitivity analyses evaluated the robustness of the treatment-effect estimate to alternative assumptions regarding baseline prognostic factors, external-control data source, matching methodology, intercurrent events, outcome ascertainment, censoring, and calendar time.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Company-presented survival analysis with broader external controls: prespecified subgroup analyses

| Subgroup analysis | Definition |
| --- | --- |
| Baseline miglustat use | “Participants with and without baseline miglustat use” |
| Source of external control data | “NIH, YODA, and French cohorts considered separately” |
| Age of neurological onset | “Early and late I-NPC subgroups considered separately” |
| Standard-of-care therapy over time | “Participants born before 2010 and born in 2010 or later” |

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Company-presented survival analysis with broader external controls: sensitivity analyses

| Sensitivity analysis | Definition |
| --- | --- |
| Baseline severity score | “Incorporation of baseline score into the matching algorithm instead of age at neurological onset” |
| Baseline severity by data source | “Source-specific baseline severity measures used in matching (YODA and Freihuber, separately)” |
| Genotype | “Incorporation of genotype category or genetic severity score instead of age at neurological onset” |
| Baseline miglustat use assumed absent | “All Vanier participants assumed to have no miglustat use at baseline” |
| One-to-one matching | “One-to-one matching in place of variable-ratio many-to-one matching” |
| Many-to-one matching without re-use | “Each external control participant used only once, rather than re-used across matched sets” |
| Percentile-based selection of controls | “Selection of controls using the 50th and 100th percentile methods” |
| Other NPC therapy | “Censoring participants at initiation of other NPC therapy” |
| Respiratory therapy | “Censoring at first use of respiratory therapy” |
| Concomitant intravenous adrabetadex | “Participants receiving concomitant IV adrabetadex excluded” |
| Censoring of external control follow-up | “Based on matched treated participants’ follow-up with one-to-one matching” |
| Tipping-point analysis | “Impute censored adrabetadex-treated participants as deaths” |
| One year after the last dose | “Censoring at 1 year after the last dose for participants treated with adrabetadex” |

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-6"></a>

##### Survival model proposed in the 2021 data request

> “The Primary survival analyses will be performed using an extended Cox model, which will include treatment (adrabetadex-treated vs untreated), category of age at onset of neurological manifestations and country (each country in the NPC Registry and the national cohorts) as covariates.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Source studies of the treated participants and follow-up in the label analysis

> “Of the 36 LEMBAZ-treated patients, 11, 2, 2, and 21 patients originally started LEMBAZ treatment in Trials 1, 2, 3, and the expanded access program, respectively.”
> “Median survival follow-up time from the index age was 5.6 years (range: 1.6 months to 9.2 years) in the LEMBAZ-treated group and 4.2 years (range: 2.5 months to 13.8 years) in the external control group.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Company-presented survival analysis with broader external controls: movement of participants between source studies

> “Two Study VTS301 Part C participants received open-label adrabetadex in Study VTS-270-302 (a 2-participant study in Costa Rica): 1 continued into the EAP.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “One Phase 1/2a patient was not in the VTS301 Part C”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Baseline characteristics of treated and matched external control participants in the label analysis

> “In both the LEMBAZ-treated group and the external control group, the mean index age was 5.7 years (range: 1 to 19 years).”
> “In both groups, most patients were White (94%); 58% of the LEMBAZ-treated patients were male and 33% of the external control patients were male; 67% of the patients had early infantile-onset NPC in both groups; 50% of the patients were concomitantly treated with miglustat at baseline in both groups.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Company-presented survival analysis with broader external controls: baseline characteristics of 72 treated and 119 matched controls

> “Baseline demographic and clinical characteristics were generally comparable between the 2 groups (Table 1)”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

| Characteristic | Adrabetadex (N=72) | External control (N=119) |
| --- | --- | --- |
| Age at onset under 2 years, n/N (%) | “32/72 (44)” | “57/119 (48)” |
| Age at onset 2 to under 6 years, n/N (%) | “40/72 (56)” | “62/119 (52)” |
| Median age at neurological onset, months (Q1, Q3) | “25 (0, 68)” | “24 (0, 68)” |
| Overall miglustat use, n/N (%) | “52/72 (72)” | “72/119 (61)” |
| Gastrostomy tube, n/N (%) | “11/50 (22)” | “6/26 (23)” |
| Respiratory therapy, n/N (%) | “9/50 (18)” | “2/26 (8)” |
| Race White, n/N (%) | “65/72 (90)” | “22/26 (85)” |
| Race other, n/N (%) | “7/72 (10)” | “4/26 (15)” |
| Region Europe, n/N (%) | “11/72 (15)” | “90/119 (76)” |
| Region North America, n/N (%) | “61/72 (85)” | “27/119 (23)” |
| Region South America, n/N (%) | “0 (0)” | “2/119 (2)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Overall survival in the label integrated survival analysis

> “LEMBAZ-treated patients had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death (Table 8 and Figure 1).”
> “Longer overall survival was observed independent of baseline miglustat use.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Outcome | LEMBAZ (N=36) | External control (N=36) |
| --- | --- | --- |
| Number of deaths (%) | “12 (33.3%)” | “24 (66.9%)” |
| Median survival time in months | “102” | “59” |
| Hazard ratio for risk of death (95% CI) | “0.45 (0.21, 0.95)” | Reference |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.3-2"></a>

##### Overall survival as stated by the FDA

> “Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death.”
> “The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group.”
> “This survival benefit was observed regardless of whether patients were also taking miglustat, a therapy used off-label in NPC.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “The analysis showed a 55 percent reduction in the risk of mortality.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-3.1.1.8.3-3"></a>

##### Company-presented survival analysis with broader external controls: overall survival in 72 treated and 119 matched controls

> “Participants treated with adrabetadex had a significantly reduced risk of death compared with external control individuals (Figure 2)”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

| Population and comparator source | Deaths, adrabetadex (%) | Deaths, external control (%) | HR (95% CI) | P-value |
| --- | --- | --- | --- | --- |
| Overall infantile | “17 (23.6%)” | “44 (61.2%)” | “0.289 (0.141, 0.593)” | “< 0.0001” |
| Early infantile | “9 (28.1%)” | “24 (76.1%)” | “0.148 (0.064, 0.343)” | “< 0.0001” |
| Late infantile | “8 (20.0%)” | “20 (49.2%)” | “0.344 (0.146, 0.812)” | “0.0457” |
| With miglustat | “8 (22.9%)” | “13 (37.9%)” | “0.361 (0.173, 0.752)” | “0.0205” |
| Without miglustat | “7 (33.3%)” | “19 (91.2%)” | “0.139 (0.049, 0.398)” | “< 0.0001” |
| French comparator | “9 (16.4%)” | “44 (80.7%)” | “0.113 (0.042, 0.301)” | “< 0.0001” |
| NIH comparator | “12 (33.3%)” | “30 (84.2%)” | “0.449 (0.214, 0.946)” | “0.0322” |
| YODA comparator | “8 (21.6%)” | “6 (16.4%)” | “0.381 (0.128, 1.137)” | “0.1426” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.8.3-4"></a>

##### Company-presented survival analysis with broader external controls: hazard ratio and five-year survival as announced

> “a 71% reduction in the risk of mortality in adrabetadex-treated patients compared with matched external controls (HR 0.289; 95% CI, 0.141-0.593; P < 0.0001)”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

> “In the previously reported analysis, a comparison of survival in individuals with infantile-onset NPC treated with adrabetadex to matched external controls showed a 71% reduction in the risk of mortality (p<0.0001).”
> “The 5-year survival rate was 84% for those treated with adrabetadex versus 42% for external controls.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.8.3-5"></a>

##### Company-presented survival analysis with broader external controls: consistency across sensitivity analyses

> “Hazard ratio (HR) estimates remained consistent with the primary analysis and supportive of a clinically meaningful survival benefit in I-NPC (HR:0.289, 95% CI:0.141-0.593, p<0.0001).”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Company-presented disease progression analysis: annual rate of change on the rescored 4-domain NPC Clinical Severity Scale

> “79 treated participants contributed R4DNPCCSS scores.”
> “Adrabetadex treatment significantly reduced the annual rate of disease progression from 1.34 units/year before treatment to 0.76 units per year after treatment (difference 0.58 units/year; 95% CI, –0.98 to –0.18; P=0.0055; Table 2), reflecting a 43% reduction in the annual rate of progression”
> “The mean estimated difference between treated and untreated trajectories of R4DNPCCSS scores after 3 years of adrabetadex treatment was −1.7 (95% CI, −2.94 to −0.53), illustrating a meaningful decrease in R4DNPCCSS scores in participants treated with adrabetadex”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “A significantly reduced annual rate of disease progression of 43% (p=0.0055) over 52 weeks compared with pre-treatment rates of disease progression.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.8.3-7"></a>

##### Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026

> “Adrabetadex was associated with a significantly reduced risk of death (Figure 2; Table 2).”
> “Overall survival showed directional consistency for the adrabetadex-treated group across all external control cohorts”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

| Population and comparator source | Deaths, treated (%) | Deaths, control (%) | Hazard ratio (95% CI) | P-value |
| --- | --- | --- | --- | --- |
| Overall infantile, pooled comparator | “9 (13.6%)” | “42 (63.3%)” | “0.162 (0.069, 0.380)” | “<0.0001” |
| Early infantile, pooled comparator | “6 (18.8%)” | “23 (72.8%)” | “0.109 (0.035, 0.333)” | “<0.0001” |
| Late infantile, pooled comparator | “3 (8.8%)” | “18 (54.3%)” | “0.148 (0.040, 0.546)” | “0.0036” |
| With miglustat | “2 (7.1%)” | “12 (41.8%)” | “0.097 (0.023, 0.406)” | “0.0005” |
| Without miglustat | “5 (21.7%)” | “18 (79.9%)” | “0.123 (0.036, 0.425)” | “<0.0001” |
| French comparator | “5 (9.8%)” | “42 (82.1%)” | “0.073 (0.023, 0.236)” | “<0.0001” |
| NIH comparator | “5 (15.2%)” | “24 (71.2%)” | “0.176 (0.060, 0.517)” | “<0.0001” |
| YODA comparator | “4 (11.4%)” | “6 (17.9%)” | “0.298 (0.082, 1.086)” | “0.1168” |

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: limitations of the integrated externally controlled survival analysis

- Design: the comparison is with external controls. A statistical methods poster on the analysis states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies, and that target trial emulation identified four principal threats: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias. Both the label analysis and the company analysis required each matched control to be alive at the treated participant's age at treatment initiation.
- Label analysis: all 26 external control participants came from Study 1 and were weighted to a number of 36 against 36 treated participants. Matching used disease subtype, age of neurological symptom onset (±3 months), and baseline miglustat use; 58% of treated and 33% of control participants were male, median follow-up from the index age was 5.6 and 4.2 years, and index ages ranged from 1 to 19 years. The label states that safety and effectiveness in reducing mortality with neurological onset at 6 years of age or older has not been established.
- Analysis with broader external controls: 72 treated participants were matched with 119 external controls drawn from 4 major disease databases or publications, and the poster states that comparability factors were not available from all sources.
- Variation in the estimate: the hazard ratio differed by comparator source (French 0.113; NIH 0.449, 95% CI 0.214 to 0.946; YODA 0.381, 95% CI 0.128 to 1.137, P = 0.1426) and between data cuts (0.162 with 66 treated participants at the June 24, 2024 cutoff; 0.289 with 72 at the January 10, 2025 cutoff). The label analysis reported 0.45 (0.21, 0.95). The statistical methods poster reported that hazard ratio estimates across its prespecified sensitivity analyses remained consistent with the primary analysis.
- Analysis plan: the YODA Project data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory” and that no minimum sample size was determined a priori.

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.9-2"></a>

#### Indication limited to neurological onset before 6 years of age

> “the safety and effectiveness of LEMBAZ to reduce mortality in patients with NPC with neurological manifestation onset at 6 years of age or older has not been established”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.9-3"></a>

#### Sources of bias in externally controlled survival analyses

> “However, externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies.”
> “Target trial emulation made the causal design explicit and identified four principal threats to inference in an externally controlled survival analysis: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.9-4"></a>

#### Incomplete comparability data across external control sources

> “Comparability factors were not available from all sources.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
